Alkermes (ALKS)
NASDAQ: ALKS
· Real-Time Price · USD
30.13
1.36 (4.73%)
At close: May 01, 2025, 12:10 PM
4.73% (1D)
| Bid | 30.02 |
| Market Cap | 4.97B |
| Revenue (ttm) | 1.56B |
| Net Income (ttm) | 367.07M |
| EPS (ttm) | 2.2 |
| PE Ratio (ttm) | 13.69 |
| Forward PE | 15.45 |
| Analyst | Buy |
| Ask | 30.26 |
| Volume | 1,379,043 |
| Avg. Volume (20D) | 1,873,665 |
| Open | 28.73 |
| Previous Close | 28.77 |
| Day's Range | 28.64 - 31.32 |
| 52-Week Range | 22.90 - 36.45 |
| Beta | 0.35 |
About ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the tre...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 1991
Employees 1,800
Stock Exchange NASDAQ
Ticker Symbol ALKS
Website https://www.alkermes.com
Analyst Forecast
According to 12 analyst ratings, the average rating for ALKS stock is "Buy." The 12-month stock price forecast is $37, which is an increase of 22.82% from the latest price.
Stock ForecastsEarnings Surprise
Alkermes has released their quartely earnings
on May 1, 2025:
Next Earnings Release
Alkermes is scheduled to release its earnings on May 1, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
Just now
Alkermes shares are trading higher after the compa...
Unlock content with
Pro Subscription
9 months ago
+6.04%
Alkermes shares are trading higher after the company reported better-than-expected Q2 financial results.
